Integration of gene expression and alternative splicing enhances IGHV mutation status and survival risk prediction in chronic lymphocytic leukemia
Open Access
- 24 July 2026
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
The immunoglobulin heavy chain variable region (IGHV) mutation status is a key prognostic marker in chronic lymphocytic leukemia (CLL), shaping disease progression and therapeutic response. Current IGHV testing relies on molecular genomic analyses and requires specific laboratory tests, limiting its accessibility. Here, we developed an unbiased computational approach to accurately predict IGHV mutation status based on gene expression and alternative splicing profiles derived from transcriptome data. We showed that predicted IGHV status had a superior predictive power for overall and failure-free survival compared to conventional IGHV testing methods. Moreover, we identified significant novel associations between key transcriptomic features and genetic lesions, indicating potential but unexplored roles in CLL pathogenesis. Our results thus highlight a novel strategy for integrating molecular features to improve CLL prognosis, underscoring the prognostic value of RNA alternative splicing in CLL biology.Keywords
This publication has 32 references indexed in Scilit:
- Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic targetLeukemia, 2021
- Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencingLeukemia, 2020
- IGHV mutational status testing in chronic lymphocytic leukemiaAmerican Journal of Hematology, 2017
- Alternative splicing: the pledge, the turn, and the prestigeHuman Genetics, 2017
- Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22Leukemia, 2016
- Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatmentLeukemia Research, 2015
- Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemiaNature Genetics, 2011
- Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromesNature Genetics, 2011
- Frequent pathway mutations of splicing machinery in myelodysplasiaNature, 2011
- Alternative isoform regulation in human tissue transcriptomesNature, 2008